FDA Class II Recall: Glenmark's Indomethacin Extended-Release Capsules Face Dissolution Failure, Raising Supply Chain Concerns
Glenmark Pharmaceuticals Inc., USA, initiated a nationwide Class II recall (D-0643-2024) for Indomethacin Extended-Release Capsules, 75 mg, due to failed dissolution specifications. This event, stemming from product manufactured by Glenmark Pharmaceuticals Limited in India, necessitates immediate action from procurement and regulatory teams to assess supply chain vulnerabilities and ensure product quality.
FDA Class II Recall: Indomethacin Extended-Release Capsules Fail Dissolution Specifications
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, has initiated a voluntary, firm-initiated Class II recall, identified as D-0643-2024, for specific lots of Indomethacin Extended-Release Capsules, USP, 75 mg. This critical regulatory action, initiated on July 31, 2024, stems from the product failing dissolution specifications, with results falling below the required limits. For procurement directors and supply chain VPs, this means an immediate assessment of current inventory levels for Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID) widely used for pain and inflammation management. The affected product, packaged in 60-count bottles (NDC 68462-325-60) and 90-count bottles (NDC 68462-325-90), was distributed nationwide across the USA. A total of 2,404 bottles from Lot#: 17240105, with an expiration date of December 31, 2025, are subject to this recall. Given the Class II classification, the FDA has determined that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This classification underscores the urgency for buyers to understand the potential impact on patient safety and market availability, prompting a rapid review of their supply chain resilience for this essential medication. For regulatory affairs heads, the failure to meet dissolution specifications is a significant quality control breach. Dissolution testing is crucial for extended-release formulations like Indomethacin Extended-Release Capsules, as it ensures the active pharmaceutical ingredient (API) is released at the intended rate, directly impacting the drug's efficacy and safety profile. Below-specification results indicate that the drug may not be absorbed correctly, potentially leading to sub-therapeutic effects or, conversely, an unintended rapid release. This event highlights the imperative for robust quality agreements and stringent oversight of contract manufacturing organizations (CMOs) or internal manufacturing sites. Businesses relying on Glenmark for Indomethacin or other generic pharmaceuticals must now scrutinize their quality assurance processes and supplier qualification programs to prevent similar issues from impacting their own product lines and market commitments.
Glenmark's Global Manufacturing Footprint and US Market Exposure
The recalled Indomethacin Extended-Release Capsules were manufactured by Glenmark Pharmaceuticals Limited at its facility located in Plot No. 2 Phase-2, Pharma Zone, SEZ, Pithampur, Dist-Dhar, Madya Pradesh - 454775, India. This Indian manufacturing site serves as a critical node in Glenmark's global supply chain, producing pharmaceuticals for various markets, including the United States, where Glenmark Pharmaceuticals Inc., USA, acts as the marketer and distributor from its Mahwah, NJ, base. For business development executives, this geographic split between manufacturing and distribution underscores the complexities and inherent risks in global pharmaceutical sourcing. A quality issue at an overseas manufacturing facility, even if the recalling firm is the US entity, directly impacts market access and brand reputation in key markets like the USA. Procurement directors must recognize that sourcing from a single manufacturing location, particularly one located internationally, introduces specific vulnerabilities. Any disruption, whether quality-related like this dissolution failure, or logistical, can have cascading effects on product availability. The Pithampur facility's role in supplying a nationally distributed product like Indomethacin means that this recall has broad implications for US healthcare providers and patients. Companies that source APIs or finished dosage forms from Glenmark's Indian facilities for their own products must conduct a thorough risk assessment. This includes evaluating the Pithampur site's overall compliance history, beyond just this specific recall, to understand the potential for broader quality system deficiencies that could impact other molecules or product lines they rely upon. Diversifying manufacturing partners and geographical sourcing is a strategic imperative to mitigate such concentrated supply chain risks.
Supply Chain Vulnerability: Indomethacin Sourcing and Mitigation Strategies
The Class II recall of Glenmark's Indomethacin Extended-Release Capsules highlights a critical vulnerability for procurement and supply chain teams reliant on generic drug manufacturers. Indomethacin, identified by its RXCUI 310992 and UNII XXE1CET956, is a widely prescribed nonsteroidal anti-inflammatory drug (NSAID) under the Cyclooxygenase Inhibitors [MoA] and Anti-Inflammatory Agents, Non-Steroidal [CS] classifications. Any disruption in its supply can impact patient access, particularly for chronic conditions where consistent medication is vital. For procurement directors, this event necessitates an immediate re-evaluation of their sourcing strategy for Indomethacin and other critical generic molecules. The 2,404 bottles recalled represent a tangible, albeit potentially limited, disruption to the nationwide USA supply. Regulatory affairs heads should be concerned about the implications of failed dissolution specifications, as this is a fundamental quality attribute. Such failures can trigger enhanced scrutiny from the FDA on Glenmark's entire quality management system, potentially leading to further regulatory actions or delays in future product approvals. This situation underscores the importance of robust supplier qualification programs that go beyond initial audits, incorporating continuous monitoring of quality metrics and regulatory compliance. Business development executives should view this as an opportunity to identify and qualify alternative suppliers for Indomethacin and similar generic NSAIDs. While specific alternative suppliers are not identified in the provided intelligence, the market for generic Indomethacin typically includes multiple manufacturers. Proactive identification and qualification of geographically diverse suppliers are essential to build resilience and avoid single-source dependencies that can lead to significant market exposure during recall events.
Regulatory Compliance Landscape and Future Scrutiny for Glenmark
This Class II recall for Indomethacin Extended-Release Capsules, USP, 75 mg, places Glenmark Pharmaceuticals Inc., USA, and its manufacturing affiliate, Glenmark Pharmaceuticals Limited, under increased regulatory scrutiny from the FDA. While this specific event is a firm-initiated voluntary recall rather than an FDA-issued Warning Letter, the underlying quality failure—failed dissolution specifications—is a serious concern that could prompt further regulatory oversight. For regulatory affairs heads, this means anticipating potential FDA questions regarding the root cause analysis, corrective and preventive actions (CAPA) implemented at the Pithampur facility, and the effectiveness check of these actions. The FDA's center classification date of August 23, 2024, and report date of September 4, 2024, indicate ongoing agency review of Glenmark's recall activities. For business development executives, a Class II recall can impact market perception and future commercial opportunities. Customers, particularly large pharmacy chains and group purchasing organizations, may reassess their confidence in Glenmark's product quality and supply reliability. This could lead to a preference for alternative suppliers, even for products not directly affected by this recall. Furthermore, future product applications (ANDA203501 for Indomethacin) from Glenmark may face more rigorous review, potentially extending approval timelines if the FDA identifies systemic quality issues. Procurement directors should factor this heightened regulatory risk into their supplier qualification and ongoing monitoring processes, understanding that a single quality event can have long-term implications for a manufacturer's standing and ability to reliably supply the market.